Send us a text

This episode of the Doc2Doc podcast features Dr. Christopher Riemann of the Cincinnati Eye Institute. Dr. Riemann shares insights into the FIXER Trial, a Phase III study evaluating the use of methotrexate to prevent proliferative vitreoretinopathy (PVR) in retinal detachment surgery.

Listeners will gain a deeper understanding of:
☑️The clinical burden of PVR and its impact on patient outcomes
☑️Methotrexate’s mechanism of action and historical use in ophthalmology
☑️The FIXER Trial’s innovative design and promising interim results
☑️Opportunities for collaboration across EyeCare Partners sites

This episode exemplifies the spirit of clinical innovation and collaboration that defines our network. We encourage all providers, researchers and team members to tune in and consider how this research may inform future practice.

+++

The program is brought to you by our Corporate Sponsor, AbbVie. The opinions of the presenters and the content shared is not created by or necessarily endorsed by AbbVie.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

For more information, visit: https://www.abbvie.com/science/areas-of-focus/eye-care.html

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

Hosts Dr. Albert Cheung (Virginia Eye Consultants) and Dr. Sara LeMay (Retina Associates of Kentucky) are joined by retina specialists Dr. Miguel Busquets (Retina Associates of Kentucky) and Dr. Boleslav (Slava) Kotlyar (Vitreous Retina Macula Specialists of New Jersey) explore photobiomodulation (PBM) and the Valeda Light Delivery System, the first FDA-authorized treatment for non-exudative (dry) age-related macular degeneration (AMD). The discussion covers the science behind PBM, using specific wavelengths of light to stimulate mitochondrial function in retinal cells, and its clinical benefits, including improved visual acuity and slowed progression of geographic atrophy.

+++

The program is brought to you by our Corporate Sponsor, AbbVie. The opinions of the presenters and the content shared is not created by or necessarily endorsed by AbbVie.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

For more information, visit: https://www.abbvie.com/science/areas-of-focus/eye-care.html

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

This episode features a dynamic conversation on two emerging technologies in glaucoma care: Direct Selective Laser Trabeculoplasty (DSLT) and the iDose implant. Hosted by Dr. Katie Rachon and Dr. Constance Okeke, both at Virginia Eye Consultants, this episode includes expert insights from Dr. Anup Khatana of the Cincinnati Eye Institute and Dr. Michael Stiles of Stiles Eyecare Excellence, who discuss clinical applications, patient selection and outcomes. This episode offers valuable guidance for eye care professionals navigating the evolving landscape of interventional glaucoma treatment.